-
Mashup Score: 12THE ONCOALERT NETWORK - 13 day(s) ago
Welcome to OncoAlert
Source: www.OncoAlert360.comCategories: General Medicine NewsTweet
-
Mashup Score: 12THE ONCOALERT NETWORK - 14 day(s) ago
Welcome to OncoAlert
Source: www.OncoAlert360.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 https://t.co/oolI5dbfui OR https://t.co/rcEUYeJ0Wd The OncoAler…
-
-
Mashup Score: 12THE ONCOALERT NETWORK - 15 day(s) ago
Welcome to OncoAlert
Source: www.OncoAlert360.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 https://t.co/oolI5dbfui OR https://t.co/rcEUYeJ0Wd The OncoAler…
-
-
Mashup Score: 9THE ONCOALERT NETWORK - 16 day(s) ago
Welcome to OncoAlert
Source: www.OncoAlert360.comCategories: General Medicine NewsTweet-
RT @OncoAlert: The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 https://t.co/oolI5dbfui OR https://t.co/rcEUYeJ0Wd The OncoAler…
-
-
Mashup Score: 96
Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage
Source: www.astrazeneca.comCategories: General Medicine NewsTweet-
It’s going to be again another #TrastuzumabDeruxtecan #TDXd year…looking forward to the full results including safety ! https://t.co/TXgSrbi9fH @OncoAlert #BreastCancer #bcsm https://t.co/zDTK3ZWU9o
-
-
Mashup Score: 96
Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage
Source: www.astrazeneca.comCategories: General Medicine NewsTweet-
It’s going to be again another #TrastuzumabDeruxtecan #TDXd year…looking forward to the full results including safety ! https://t.co/TXgSrbi9fH @OncoAlert #BreastCancer #bcsm https://t.co/zDTK3ZWU9o
-
-
Mashup Score: 94
Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage
Source: www.astrazeneca.comCategories: General Medicine NewsTweet-
It’s going to be again another #TrastuzumabDeruxtecan #TDXd year…looking forward to the full results including safety ! https://t.co/TXgSrbi9fH @OncoAlert #BreastCancer #bcsm https://t.co/zDTK3ZWU9o
-
-
Mashup Score: 90Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study - 1 month(s) ago
Very limited data exist on assisted reproductive technology (ART) use in BRCA1/2 carriers conceiving after breast cancer. This study aimed to investigate the safety of ART to achieve a pregnancy after breast cancer in BRCA1/2 carriers.
Source: www.ejcancer.comCategories: General Medicine NewsTweet-
Finally out in @ElsevierConnect #EJC results of the #BRCABCYcollaboration presented at #ESMOBreast24 reporting on safety of #oncofertility techniques in young #BRCA carriers with #BreastCancer...free link here: https://t.co/DLxNfWzRr4 @OncoAlert @AIRC_it @UniGenova @SanMartino_Ge https://t.co/lCKjR3Y8c1
-
-
Mashup Score: 11
AbstractBackground. The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences
Source: academic.oup.comCategories: General Medicine NewsTweet-
RT @mirrorsmed: Prognostic implications of risk definitions from the monarchE and NATALEE trials https://t.co/P8EEcBY3Fj Study compared t…
-
-
Mashup Score: 11
AbstractBackground. The monarchE and NATALEE trials employed different high-risk inclusion criteria. The main objective is to assess prognostic differences
Source: academic.oup.comCategories: General Medicine NewsTweet-
RT @mirrorsmed: Prognostic implications of risk definitions from the monarchE and NATALEE trials https://t.co/P8EEcBY3Fj Study compared t…
-
RT @OncoAlert: The OncoAlert🚨DAILY Newsletter at #ASCO25, REGISTER HERE 👉 https://t.co/oolI5dbfui OR https://t.co/rcEUYeJ0Wd The OncoAler…